Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

2 treatments under study, led by Virusspecific Cytotoxic T Lymphocytes Vctls

Related Conditions

Often studied with 18 related conditions

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 2 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed with results

Key Signals

100% success

Data Visualizations

Phase Distribution

1Total
Early Phase 1 (1)

Trial Status

Not Yet Recruiting1
Completed1

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 1 completed trials

Clinical Trials (2)

Showing 2 of 2 trials
NCT07873970Early Phase 1Not Yet Recruiting

25BT056: Basket Study of Viral Cytotoxic T Lymphocytes

NCT04295733CompletedPrimary

Safety, Tolerability and Immunogenicity of 4CMenB Vaccine(2 Doses) in Adults With an Immunodeficiency

Showing all 2 trials

Research Network

Common Treatments

  • Virusspecific Cytotoxic T Lymphocytes Vctls1
  • 4cmenb Bexsero Vaccine1

Active Sponsors

  • Ospedale Policlinico San Martino1
  • GSK1
  • Children's Hospital of Philadelphia1

Top Investigators

Related Conditions

  • Epstein Barr Virus Infection1
  • Posttransplant Lymphoproliferative Disorder1
  • Solid Organ Transplant Complications1
  • Adenovirus1
  • Bk Virus Infection1

Activity Timeline